Analyst Price Targets — CRDL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 23, 2024 6:52 am | Edward Nash | Canaccord Genuity | $8.00 | $2.24 | StreetInsider | Cardiol Therapeutics (CRDL) PT Raised to $8 at Canaccord Genuity |
Latest News for CRDL
Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describing the program as a key step toward a potential new drug application.
Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) is expected to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors can check the company's upcoming Q2 2026 earning report page for the latest details on the call
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT. Canaccord…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CRDL.
Senate Trading
No Senate trades found for CRDL.
U.S. House Trading
No House trades found for CRDL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.